Glaukos Corporation $GKOS Shares Bought by Russell Investments Group Ltd.

Russell Investments Group Ltd. lifted its position in Glaukos Corporation (NYSE:GKOS) by 174.9% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 38,393 shares of the medical instruments supplier’s stock after acquiring an additional 24,428 shares during the quarter. Russell Investments Group Ltd.’s holdings in Glaukos were worth $3,779,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Nuveen LLC acquired a new position in Glaukos during the 1st quarter valued at approximately $31,474,000. Westfield Capital Management Co. LP boosted its position in Glaukos by 34.3% during the 1st quarter. Westfield Capital Management Co. LP now owns 1,084,184 shares of the medical instruments supplier’s stock valued at $106,705,000 after purchasing an additional 277,033 shares during the period. Gilder Gagnon Howe & Co. LLC boosted its position in Glaukos by 25.3% during the 4th quarter. Gilder Gagnon Howe & Co. LLC now owns 825,276 shares of the medical instruments supplier’s stock valued at $123,742,000 after purchasing an additional 166,677 shares during the period. Voya Investment Management LLC increased its holdings in shares of Glaukos by 266.2% in the 4th quarter. Voya Investment Management LLC now owns 200,698 shares of the medical instruments supplier’s stock worth $30,093,000 after acquiring an additional 145,890 shares during the period. Finally, Comerica Bank increased its holdings in shares of Glaukos by 664.5% in the 4th quarter. Comerica Bank now owns 151,538 shares of the medical instruments supplier’s stock worth $22,722,000 after acquiring an additional 131,715 shares during the period. Institutional investors and hedge funds own 99.04% of the company’s stock.

Glaukos Trading Up 4.9%

Shares of Glaukos stock opened at $94.2070 on Friday. The company has a quick ratio of 4.69, a current ratio of 5.51 and a debt-to-equity ratio of 0.09. The firm has a market cap of $5.40 billion, a price-to-earnings ratio of -57.10 and a beta of 0.78. The business has a fifty day simple moving average of $96.26 and a 200-day simple moving average of $101.46. Glaukos Corporation has a fifty-two week low of $77.10 and a fifty-two week high of $163.71.

Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.02. The business had revenue of $124.12 million during the quarter, compared to analyst estimates of $115.49 million. Glaukos had a negative return on equity of 8.59% and a negative net margin of 21.43%.The company’s revenue was up 29.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.52) earnings per share. Glaukos has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Glaukos Corporation will post -1.08 EPS for the current fiscal year.

Analysts Set New Price Targets

GKOS has been the topic of a number of analyst reports. Morgan Stanley dropped their price objective on shares of Glaukos from $110.00 to $72.00 and set an “underweight” rating on the stock in a report on Tuesday, May 6th. Needham & Company LLC dropped their price objective on shares of Glaukos from $176.00 to $115.00 and set a “buy” rating on the stock in a report on Thursday, May 1st. Mizuho set a $130.00 price objective on shares of Glaukos in a report on Thursday, July 31st. UBS Group increased their price objective on shares of Glaukos from $125.00 to $134.00 and gave the stock a “buy” rating in a report on Thursday, July 31st. Finally, Stifel Nicolaus reduced their price target on Glaukos from $140.00 to $115.00 and set a “buy” rating for the company in a research report on Thursday, May 1st. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $127.42.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.